Medtronic InFuse New Technology Add-On Payment Hinges On FDA Approval
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's InFuse bone graft/LT-Cage lumbar tapered fusion device will be the first product to receive a new technology "add-on" payment under the inpatient prospective payment system (IPPS), provided FDA grants the device PMA approval before publication of the FY 2003 final rule
You may also be interested in...
Medtronic InFuse PMA Approval Sets Up CMS “New Technology” Add-On
FDA's July 2 approval of Medtronic Sofamor Danek's InFuse bone graft/LT-Cage lumbar tapered fusion system arrives in time for the device to qualify for a Medicare "new technology" add-on payment
Medtronic InFuse PMA Approval Sets Up CMS “New Technology” Add-On
FDA's July 2 approval of Medtronic Sofamor Danek's InFuse bone graft/LT-Cage lumbar tapered fusion system arrives in time for the device to qualify for a Medicare "new technology" add-on payment
Device Inpatient Payment, Medicare Contractor Reforms Pass With Drug Bill
The Senate will take up Medicare contractor and inpatient prospective payment reform proposals within the "Medicare Modernization and Prescription Drug Act" of 2002 (HR 4954) after the July 4 recess